

Norah E Palmateer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9332644/publications.pdf>

Version: 2024-02-01

44
papers

2,579
citations

304368

22
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

2699
citing authors

#	ARTICLE	IF	CITATIONS
1	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , 2014, 43, 235-248.	0.9	298
2	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , 2011, 106, 1978-1988.	1.7	271
3	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	1.7	242
4	Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , 2014, 25, 34-52.	1.6	238
5	Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. <i>Addiction</i> , 2010, 105, 844-859.	1.7	209
6	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	1.5	158
7	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1397-1409.	4.6	147
8	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , 2016, 65, S33-S45.	1.8	146
9	Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions. <i>PLoS ONE</i> , 2014, 9, e104515.	1.1	79
10	Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. <i>Journal of Viral Hepatitis</i> , 2014, 21, 25-32.	1.0	58
11	Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis. <i>Journal of Infectious Diseases</i> , 2018, 217, 1875-1882.	1.9	50
12	Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. <i>Lancet HIV</i> , the, 2019, 6, e315-e324.	2.1	50
13	Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. <i>Journal of Hepatology</i> , 2013, 58, 460-466.	1.8	42
14	Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. <i>International Journal of Drug Policy</i> , 2012, 23, 346-352.	1.6	39
15	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
16	Infections with Spore-forming Bacteria in Persons Who Inject Drugs, 2000-2009. <i>Emerging Infectious Diseases</i> , 2013, 19, 29-34.	2.0	37
17	Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102663.	1.6	36
18	Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing. <i>Drug and Alcohol Dependence</i> , 2013, 133, 172-179.	1.6	32

#	ARTICLE	IF	CITATIONS
19	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings—what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	1.7	30
20	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) — a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30
21	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , 2021, 116, 2893-2907.	1.7	28
22	The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. <i>BMC Public Health</i> , 2010, 10, 721.	1.2	26
23	Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. <i>International Journal of Drug Policy</i> , 2015, 26, 1041-1049.	1.6	25
24	Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 174, 91-97.	1.6	25
25	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <i>Journal of Hepatology</i> , 2022, 76, 549-557.	1.8	24
26	Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. <i>International Journal of Drug Policy</i> , 2013, 24, 85-100.	1.6	23
27	Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. <i>Addiction</i> , 2018, 113, 80-90.	1.7	23
28	Anthrax Infection Among Heroin Users in Scotland During 2009-2010: A Case-Control Study by Linkage to a National Drug Treatment Database. <i>Clinical Infectious Diseases</i> , 2012, 55, 706-710.	2.9	21
29	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 971-980.	1.9	20
30	Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. <i>Public Health</i> , 2021, 190, 132-134.	1.4	18
31	A Decade of Spore-Forming Bacterial Infections Among European Injecting Drug Users: Pronounced Regional Variation. <i>American Journal of Public Health</i> , 2012, 102, 122-125.	1.5	17
32	Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: A systematic review. <i>International Journal of Drug Policy</i> , 2011, 22, 102-108.	1.6	15
33	Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2018, 113, 2118-2131.	1.7	15
34	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. <i>International Journal of Drug Policy</i> , 2018, 52, 115-122.	1.6	13
35	Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109263.	1.6	13
36	High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs. <i>International Journal of Drug Policy</i> , 2021, 90, 102731.	1.6	10

#	ARTICLE	IF	CITATIONS
37	The association between alcohol use and hepatitis C status among injecting drug users in Glasgow. <i>Drug and Alcohol Dependence</i> , 2012, 123, 180-189.	1.6	6
38	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	2.5	6
39	Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. <i>International Journal of Drug Policy</i> , 2021, 96, 103304.	1.6	4
40	National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. <i>Public Health</i> , 2021, 198, 102-105.	1.4	4
41	National population prevalence of antibodies to SARS-CoV-2 among pregnant women in Scotland during the second wave of the COVID-19 pandemic: a prospective national serosurvey. <i>Public Health</i> , 2021, 199, 17-19.	1.4	4
42	The uptake of foil from needle and syringe provision services and its role in smoking or snorting heroin among people who inject drugs in Scotland. <i>International Journal of Drug Policy</i> , 2021, 98, 103369.	1.6	4
43	Exploring Associations Between Perceived HCV Status and Injecting Risk Behaviors Among Recent Initiates to Injecting Drug Use in Glasgow. <i>Substance Use and Misuse</i> , 2008, 43, 375-388.	0.7	3
44	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2018, 53, 45-54.	1.6	2